Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation

Tepotinib (Tepmetko™, Merck) is a potent inhibitor of c-Met (mesenchymal−epithelial transition factor). In March 2020, tepotinib (TEP) was approved for use in Japan for the treatment of patients who suffered from non-small cell lung cancers (NSCLC) harboring an MET exon 14 skipping alteration and ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhameed, Ali S., Attwa, Mohamed W., Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663698/
https://www.ncbi.nlm.nih.gov/pubmed/33126762
http://dx.doi.org/10.3390/molecules25215004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663698/
https://www.ncbi.nlm.nih.gov/pubmed/33126762
http://dx.doi.org/10.3390/molecules25215004

Ejemplares similares